EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer
NCT07739563
Behavior, Breast Cancer
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT Number: NCT07088978
The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.
Trial opening soon.
Get NotifiedThe scale validity of the study will be evaluated through language and content validity, construct validity, criterion validity, and known-group validity methods; while the scale reliability will be assessed by calculating the Cronbach's alpha and McDonald's omega reliability coefficients.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 12 months
Language and Content Validity: To assess the relevance and appropriateness of the translated items, a panel of at least six experts in oncology, psychology, and instrument development will evaluate each item.
Time frame: Through study completion, an average of 12 months
Content Validity Index (CVI) will be calculated based on expert ratings to determine the proportion of items deemed relevant.
Time frame: Through study completion, an average of 12 months
Content Validity Ratio (CVR) will be used to assess whether each item is essential for measuring the construct.
Time frame: Through study completion, an average of 12 months
Confirmatory Factor Analysis (CFA) will be performed to verify whether the factor structure of the Turkish version aligns with that of the original instrument.
Model fit indices such as χ²/df, RMSEA, CFI, TLI, and SRMR will be used to evaluate the adequacy of the factor structure.
Time frame: Through study completion, an average of 12 months
The Turkish PROFFIT scores will be correlated with other established patient-reported outcome measures, specifically the COST (v2) and EORTC QLQ-C30 instruments, to assess convergent validity.
Pearson or Spearman correlation coefficients will be used to determine the strength of associations between PROFFIT and these validated measures.
Time frame: Through study completion, an average of 12 months
To assess whether the instrument can differentiate between groups with known differences in financial toxicity, mean scores of the total and subscales will be compared across predefined demographic and clinical groups.
Independent samples t-tests and ANOVA will be performed to compare group differences.
Time frame: Through study completion, an average of 12 months
Internal Consistency: The reliability of the Turkish PROFFIT instrument will be evaluated using:
Cronbach's alpha (α) to assess the overall internal consistency of the scale. McDonald's omega (ω) as an alternative measure that provides a more robust estimation of reliability in multidimensional scales.
Contact information is provided by the study sponsor or research team.
Akdeniz University
Other
Adaptation of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) Instrument Into Turkish: A Validity and Reliability Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739563
Behavior, Breast Cancer
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07739849
Cancer, Hemic and Lymphatic Diseases
View Trial DetailsNCT07735442
Cancer, Neoplasms
Boston, Massachusetts, United States
View Trial DetailsNCT07731425
Cancer, Neoplasms
Boston, Massachusetts, United States
View Trial Details